Full Press Release Details
SAN FRANCISCO , Feb. 11, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.m. Pacific Time , during the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU), which will be held February 14-16, 2019 at Moscone West in San Francisco, CA. The event will follow a presentation of preliminary efficacy, safety and immune monitoring data from the ongoing urothelial carcinoma patient cohort in the PIVOT-02 study evaluating bempegaldesleukin* (NKTR-214) in combination with nivolumab.
Analyst Call with Urothelial Cancer Specialist:
Date and Time: Friday, February 15, 2019 at 2:00 p.m. Pacific Time Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international) Passcode: 9688945
The conference call will include PIVOT-02 investigator Arlene O. Siefker-Radtke , M.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and Clinical Co-leader of the Bladder Cancer SPORE Executive Committee. The webcast and slides for the conference call can be accessed through a link that is posted on the Investors section of the Nektar website at https://ir.nektar.com/events-and-presentations/events . The web broadcast of the conference call will be available for replay through March 15, 2019 .
Details on the Data Presentation at ASCO-GU:
Abstract Title: NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02 Abstract #: 388 Presenter: Arlene O. Siefker-Radtke, M.D., The University of Texas MD Anderson Cancer Center Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers Poster Board : G1 Date and Time: Friday, February 15, 2019 , 12:15-1:45 p.m. and 5:15-6:15 p.m. Pacific Time
About Nektar Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at www.nektar.com .
For Investors: Jennifer Ruddock of Nektar Therapeutics 415-482-5585 - or - Ashleigh Barreto of Nektar Therapeutics 628-895-0694
SOURCE Nektar Therapeutics